Company intelligence / Profile preview

Centrexion Therapeutics

Ownership: Private
Employees: ~24
Development stage: Phase 2

Overview

Centrexion’s lead asset CNTX‑4975 has demonstrated significant and durable relief from moderate-to-severe knee osteoarthritis pain by the second day post-injection. The VICTORY Phase III program includes three pivotal trials evaluating efficacy and safety. Other pipeline assets are advancing through early to mid-stage clinical development targeting additional chronic/inflammatory/neuropathic indications with non-opioid mechanisms.

Therapeutic areas: DermatologyImmunologyNeurologyRheumatology
Modalities: Small molecules (e.g., SSTR4 agonist, CCR2 antagonist)Topical gel (lidocaine formulation)Cannabinoid agonistsTRPV1 agonist (capsaicin)
Industry: Biotech

Drug pipeline

6 assets

CNTX-6970

5 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly & Co. – licensing deal for CNTX–0290

Beyond the preview

Go deeper on Centrexion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centrexion Therapeutics.

Explore the full profile